Company Profile

Orphee SA is a Switzerland-based company engaged in development and marketing of instrumentation for the haematology diagnostics. The Company operates in over 100 countries worldwide, including Brazil, Bangladesh, China, Philippines, Mexico, Romania, Poland, among others, and is primarily engaged in in-vitro diagnostics (IVD) market. It divides its business into three segments: Sale and Production of Haematology and Electrolyte Analyzers, offering six types of analyzers under the name Mythic (Mythic 18, Mythic 18 Vet, Mythic 22 OT, Mythic 22 CT, Mythic 22 AL, Mythic Lyte); Sale and Production of Blood Test Reagents, and Sale of Spare Parts for Offered Analyzers. The Company is a subsidiary of PZ Cormay SA. On September 1, 2014, the Company acquired 100% stake in TT Management Sp z o o to enable execution of the restructuring plan of Cormay group which aims at transferring production and distribution activity of Cormay group to Orphee.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

17/11/20	PZ Cormay S.A. acquired unknown minority stake in Orphée SA for CHF 1.2 million.	CI
06/02/20	PZ Cormay S.A. completed the acquisition of 0.54% stake in Orphée SA for PLN 0.37 million.	CI
11/12/19	PZ Cormay S.A. made a tender offer to acquire remaining 2.9% stake in Orphée SA for PLN 2 million.	CI
05/09/19	PZ Cormay S.A. agreed to acquire remaining 11.6% stake in Orphée SA for PLN 7.8 million.	CI
13/05/19	MED II, managed by ArchiMed SAS completed the acquisition of DIESSE Diagnostica Senese S.p.A. from Orphée SA and founders for €14.5 million.	CI
27/02/19	Orphée Is In Talks To Sell Stake In DIESSE	CI
28/09/18	MED II, managed by ArchiMed SAS signed a letter of intent to acquire DIESSE Diagnostica Senese S.p.A. from Orphée SA and founders.	CI
18/05/17	PZ Cormay S.A. cancelled the acquisition of an additional 12.95% stake in Orphée SA from TTL 1 SP Z O O.	CI
18/05/16	PZ Cormay S.A. signed an agreement to acquire additional 12.95% stake in Orphée SA from TTL 1 SP Z O O for PLN 10 million.	CI
02/09/15	Orphée SA completed the acquisition of TT Management sp. z o.o. from Planezza SA.	CI
10/07/15	Tadeusz Tuora sold 6.6% stake in Orphée SA for PLN 2.1 million.	CI
03/04/15	Tranche Update on Orphée SA's Equity Buyback Plan announced on February 23, 2015.	CI
03/04/15	Orphée SA's Equity Buyback announced on February 26, 2015, has expired with repurchase of 3,859,118 shares, for PLN 34.3 million.	CI

Director	Title	Age	Since
Krzysztof Ksawery Rudnik BRD	Director/Board Member	49	-
Wojciech Suchowski BRD	Director/Board Member	-	01/01/2015
Flavio Finotello CHM	Chairman	-	01/01/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORPHÉE SA	-3.55%	-53.18%	-	-	4.91M
SARTORIUS AG	+2.48%	+7.79%	+17.94%	-20.70%	17.28B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+3.87%	-5.71%	+14.03%	+97.04%	1.68B
QUIDELORTHO CORPORATION	+0.66%	+2.11%	-36.31%	-79.00%	1.25B
ECKERT & ZIEGLER SE	+0.81%	-5.80%	-32.65%	+25.81%	1.06B
CONTEC MEDICAL SYSTEMS CO.,LTD	+2.92%	-2.22%	-29.25%	-53.82%	626M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	+3.91%	-4.74%	-39.86%	-56.00%	555M
VAREX IMAGING CORPORATION	+0.23%	+2.05%	+38.21%	-53.04%	466M
REVENIO GROUP OYJ	+1.76%	+0.64%	-54.58%	-59.83%	380M
CELLAVISION AB	-0.36%	-3.77%	-22.99%	-25.81%	342M
Average	+1.30%	-0.88%	-16.16%	-25.04%	2.63B
Weighted average by Cap.	+2.29%	+4.44%	+8.57%	-16.35%

Orphée SA Stock

Stocks

ORP

CH0197761098

Advanced Medical Equipment & Technology

Latest news : Orphée SA

Quotes and Performance

Managers and Directors: Orphée SA

Medical Diagnostic & Testing Equipment

Company Profile